PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors

Patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a poor overall prognosis despite chemotherapy and radiotherapy (e.g., peptide receptor radionuclide therapy (PRRT)). Better treatment options are needed to improve disease regression and patient survival. The p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cells
Autores principales: Chow, Zeta, Johnson, Jeremy, Chauhan, Aman, Izumi, Tadahide, Cavnar, Michael, Weiss, Heidi, Townsend, Courtney M., Anthony, Lowell, Wasilchenko, Carrigan, Melton, Matthew L., Schrader, Jörg, Evers, B. Mark, Rychahou, Piotr
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8160730/
https://ncbi.nlm.nih.gov/pubmed/34065268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10051261
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares